Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07390890

DSLT for Reducing Medication in Glaucoma

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.

The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.

Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Primary Open Angle Glaucoma Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension

Sex eligibility

All sexes

Study type

Observational

Primary location

The Eye Institute of West Florida

Largo, Florida, 33770, United States

Location status: Recruiting

Location contact

Neel Desai, MD

PRINCIPAL_INVESTIGATOR

Renee Bondurant

CONTACT

[email protected]

727-450-4668

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients scheduled to undergo DSLT treatment in one or both eyes.
  • Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
  • Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.

Exclusion criteria

  • Previous glaucoma surgeries/interventions:
  • Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
  • Patients who have undergone cataract surgery within the prior 2 years.
  • Secondary glaucoma:
  • Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
  • Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

Treatment and study plan

Voyager DSLT

Device

Voyager DSLT

Primary outcomes

  1. Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP)

    Time frame: 6 months post-DSLT treatment

    The primary outcome will be assessed by comparing the number of medications needed to maintain target IOP before and after DSLT treatment.

Secondary outcomes

  1. Change in intraocular pressure (IOP) from baseline

    Time frame: 6 months post-DSLT treatment

    IOP will be measured using Goldmann applanation tonometry at each follow-up visit.

  2. Proportion of eyes needing medication stratified by number of IOP medications required

    Time frame: 6 months post-DSLT treatment

  3. Number and type of Secondary surgical interventions

    Time frame: 6 months post-DSLT treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Renee Bondurant

CONTACT

[email protected]

727-450-4668

Sponsors and collaborators

Lead sponsor

The Eye Institute of West Florida

Other

Collaborators

  • Sengi

Registry information

Official study title

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Feb 5, 2026
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.